Achieve Flexible, Optimized Manufacturing Capacity For CAR-T Therapies

By Julia Yearwood, Process Engineer, Integrated Project Services

In the cell and gene therapy space, the complexity of the production of many of these advanced therapies requires manufacturing solutions that optimize space utilization, workflows, and supply chain management. For CAR-T therapies in particular, this equation is fraught with considerations that can, when not addressed early and comprehensively, serve to inflate costs and undermine production volume and success rates.

As more CAR-T therapies are introduced to the market to treat increasingly diverse illnesses, the need for new facilities to accommodate this demand will likely surge in the next several years. This reality can create significant bottlenecks, as many of the CROs and CDMOs that companies may partner with for smaller scales need more capacity, resources, and expertise to ratchet production of these drugs up quickly or seamlessly. As a result, most companies looking to produce hundreds or thousands of doses of CAR-T treatments per year will need to construct dedicated facilities designed with their treatment in mind.